Tag: direct oral anticoagulant (DOAC)

1. Low dose edoxaban was superior to placebo in preventing stroke or systemic embolism for very elderly patients with nonvalvular atrial fibrillation at risk of bleeding. 2. Edoxaban did not significantly increase the incidence of major bleeding compared to placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: Atrial fibrillation and age are...
1. In this randomized study comparing the efficacy of rivaroxaban with warfarin, dose-adjusted rivaroxaban treatment resulted in near doubling of risk for recurrent thrombosis. 2. The two treatment groups experienced similar bleeding outcomes, but patients in the rivaroxaban group had a higher stroke incidence rate. Evidence Rating Level: 1 (Excellent) Study Rundown: Antiphospholipid...
1. In this randomized study comparing the efficacy of rivaroxaban with warfarin, dose-adjusted rivaroxaban treatment resulted in near doubling of risk for recurrent thrombosis. 2. The two treatment groups experienced similar bleeding outcomes, but patients in the rivaroxaban group had a higher stroke incidence rate. Evidence Rating Level: 1 (Excellent) Study Rundown:...
1. The Perioperative Anticoagulation Use for Surgery Evaluation (PAUSE) cohort study evaluated the safety of standardized perioperative interruption of direct oral anticoagulants (DOACs) for patients with atrial fibrillation undergoing operative interventions. The rates of both major bleeding and arterial thrombosis were low during the study period. 2. Most patients had...
1. In this retrospective observational study, direct oral anticoagulant use for atrial fibrillation in patients with mitral stenosis was linked with decreased mortality and fewer thromboembolic events compared to warfarin.  2. There was also a non-significant trend towards fewer episodes of intracranial hemorrhage with direct oral anticoagulant use. Evidence Rating Level:...